新一期英國在線科學(xué)期刊《自然—通訊》（Nature Communications）發(fā)表了日本的一個研究小組的研究報告,，他們發(fā)現(xiàn)了大腸癌,、乳腺癌,、白血病（俗稱“血癌”）等10種癌細胞容易吸收的肽,，這將有助于這些癌癥的早期發(fā)現(xiàn)與治療,。
綜合日本媒體報道，日本愛知縣癌癥中心研究所、琉球大學(xué)等機構(gòu)的研究人員以溶液中氨基酸排列方式不同的1萬億種肽為對象,，研究各種癌細胞對它們吸收的難易程度,，結(jié)果發(fā)現(xiàn)白血病細胞容易吸收肽CPP44。
研究人員讓能夠抑制癌細胞增殖的抗癌物質(zhì)與CPP44結(jié)合,，以治療患白血病的實驗鼠,。結(jié)果，實驗鼠體內(nèi)的癌細胞得以更充分地吸收抗癌物質(zhì),，癌組織縮小到原先的５0%至30%,，實驗鼠生存時間有所延長。同時,，這種治療未引發(fā)明顯的副作用,。
通過這項研究，科研人員找到了大腸癌,、乳腺癌,、肺癌等10種癌細胞容易吸收的特定種類的肽。參與研究的腫瘤病理學(xué)專家近藤英作介紹說,，此前研究者發(fā)現(xiàn)易被癌細胞吸收的肽同時也易被正常細胞吸收,，找到只容易被癌細胞吸收的肽十分不易。
研究人員指出,，利用這些肽承擔(dān)抗癌藥物“搬運工”,，能使藥物被集中送達癌細胞，有助于抑制副作用,。另外,，即使腫瘤體積還很小，如果讓這些肽與色素相結(jié)合并注入肌體,，就能使腫瘤組織變色且便于觀察,，從而幫助盡早發(fā)現(xiàn)癌癥。（生物谷Bioon.com）
doi:10.1038/ncomms1952
PMC:
PMID:
Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems
Eisaku Kondo,1, 2 Ken Saito,1 Yuichi Tashiro,3 Kaeko Kamide,4 Shusei Uno,4 Tomoko Furuya,5 Masao Mashita,6 Kiichiro Nakajima,7 Tomoyuki Tsumuraya,8 Naoya Kobayashi,9 Masahiro Nishibori,10 Mitsune Tanimoto11 & Masayuki Matsushita8
Cell-penetrating peptides have gained attention owing to their promise in noninvasive delivery systems. Among the identified cell-penetrating peptides, the TAT peptide has been preferentially used for transduction into cells of diverse origins. However, this activity is nonselective between neoplastic and non-neoplastic cells. Here we describe artificial cell-penetrating peptides that are selectively and efficiently incorporated into human tumour cells, according to their lineage. Ten representative tumour lineage-homing cell-penetrating peptides were obtained by screening of a random peptide library constructed using messenger RNA display technology, and some of the isolates were further modified by amino-acid substitution. Their advantageous tumour cell-targeting ability is corroborated in an in vivo mouse model for imaging and growth suppression of metastatic xenoplant tumours. These cell-penetrating peptides are potentially useful for the efficient targeting of human neoplasms in a tumour origin-dependent manner, and provide a framework for the development of peptide-based anti-tumour technologies.
